✦ LIBER ✦

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

✍ Scribed by Ohtake, S.; Miyawaki, S.; Fujita, H.; Kiyoi, H.; Shinagawa, K.; Usui, N.; Okumura, H.; Miyamura, K.; Nakaseko, C.; Miyazaki, Y.; Fujieda, A.; Nagai, T.; Yamane, T.; Taniwaki, M.; Takahashi, M.; Yagasaki, F.; Kimura, Y.; Asou, N.; Sakamaki, H.; Handa, H.; Honda, S.; Ohnishi, K.; Naoe, T.; Ohno, R.

Book ID: 121679031
Publisher: American Society of Hematology
Year: 2011
Tongue: English
Weight: 194 KB
Volume: 117
Category: Article
ISSN: 0006-4971
DOI: 10.1182/blood-2010-03-273243

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized trial of response-oriented in

Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study

✍ Shigeki Ohtake; Shuichi Miyawaki; Hitoshi Kiyoi; Yasushi Miyazaki; Hirokazu Okum 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 263 KB

A randomized, postremission comparison o

A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia : The Japan Adult Leukemia Study Group AML97 study

✍ Shuichi Miyawaki; Hisashi Sakamaki; Shigeki Ohtake; Nobuhiko Emi; Fumiharu Yagas 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB 👁 1 views

Phase II evaluation of an intensified in

Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500)

✍ Stephen H. Petersdorf; Cathryn Rankin; David R. Head; Howard R. Terebelo; Cheryl 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 2 views

Bortezomib Added to Daunorubicin and Cyt

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

✍ Attar, E. C.; Johnson, J. L.; Amrein, P. C.; Lozanski, G.; Wadleigh, M.; DeAngel 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 230 KB

High-dose cytosine arabinoside and dauno

High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the southeastern cancer study group

✍ Hillard M. Lazarus; W. Ralph Vogler; C. Patrick Burns; Elliott F. Winton 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

Clofarabine in combination with a standa

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

✍ Willemze, R.; Suciu, S.; Muus, P.; Halkes, C. J. M.; Meloni, G.; Meert, L.; Karr 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 197 KB